Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 650 million yuan, representing a year-on-year increase of 0.12%. Net profit attributable to shareholders of the listed company reached 16.804 million yuan, up 34.77% year-on-year. Net profit attributable to shareholders excluding non-recurring gains and losses was 14.4073 million yuan, surging 125.07% compared to the same period last year. Basic earnings per share stood at 0.0174 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments